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Abstract
The current medical therapy used in Crohn’s disease and ulcerative colitis comprises drugs that
interfere with immune response and therefore caution is needed for infectious side effects, and
where possible, strategies to prevent their occurrence should be undertaken. Last year, international
consensus guidelines on this topic were published by the European Crohn’s and Colitis Organisation.
Introduction and context
Biological therapies can no longer be disregarded in the
management of inflammatory bowel disease (IBD) and
have become – together with the 5-aminosalicylates
(5-ASAs), methotrexate, and purine analogues (azathiopr-
ine and 6-mercaptopurine) – the cornerstone of IBD
treatment. Corticosteroids, though abandoned more and
more,maystillbeusedasefficaciousinductionagentsoras
a bridge to the action of immunomodulators (or as both).
Given that the mentioned drugs, with the exception of
5-ASAs, affect theimmunityof thepatient and that there is
increasing use of these drugs in IBD, safety concerns
include the occurrence of (opportunistic) infections, and
physicians should take active measures to prevent or treat
these infections. Moreover, as many patients now enjoy a
very good quality of life as a consequence of the
therapeutic advances made, travel and vaccination advice
become part of the follow-up of patients with IBD.
Prevention of opportunistic infection includes recognizing
risk factors for infection, closely monitoring patients
during therapy (clinical and lab), and vaccinating where
possible. Risk factors for opportunistic infections include
combined immunomodulator use, including corticoster-
oids, older age, malnutrition, and comorbidities [1].
Recent advances
The best-documented infectious complication of anti-
tumor necrosis factor (anti-TNF) agents (infliximab,
adalimumab, and certolizumab pegol) is the reactivation
of latent tuberculosis (TB). By February 2003, active TB
was reported in 350 of more than 400,000 patients
treated with infliximab, a cumulative incidence of 0.46
per 1000 patient-years. Most cases will occur within the
first 2 months after initiation of therapy and are
associated with a substantial rate of mortality. Therefore,
all patients who will undergo treatment with an anti-TNF
agent should be questioned and evaluated for latent TB
with a tuberculin skin test or interferon-gamma release
assay and chest X-ray [2]. Treatment of latent TB should
be initiated at least 2 weeks prior to therapy. Recom-
mendations for screening TB and treatment are proposed
by national scientific organizations and authorities, and
their national guidelines should be consulted by
physicians.
The largest long-term study on safety of anti-TNF from
clinical practice was done in 743 infliximab-treated IBD
patients and an equally sized control group of non-anti-
TNF-treated IBD patients [3]. With a follow-up of as long
as 14 years, concomitant steroid therapy was the only
independent risk factor for infections in the infliximab
group, with a 2.69-fold (95% confidence interval [CI]
1.18-6.12) increased risk in the case of co-administration
of corticosteroids together with infliximab (P = 0.018).
Likewise, a recent cohort study from British Columbia,
Canada, showed that corticosteroids tripled the risk of
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6.1) compared withother immunosuppressant agents [4].
The European Crohn’s and Colitis Organisation
(ECCO) consensus on opportunistic infections in IBD
brought 30 IBD and infectious disease specialists
together. Their guidelines recommend serology testing
for specific viruses and administration of a number of
vaccinations shortly following the diagnosis of IBD.
The reason for doing this at an early stage is that at
least half of the patients will require immunomodu-
lators or anti-TNF (or both) during their further disease
course and live-attenuated vaccines (yellow fever and
varicella being the two most important ones) cannot
be administered during this treatment. Second, immu-
nomodulators or biological agents (or both) may
attenuate the response to vaccination. Figure 1
summarizes which serologies should be checked and
which vaccines are recommended [2,5]. Besides the
serologies that should be checked (Figure 1), a baseline
laboratory exam, including neutrophil, eosinophil, and
lymphocyte blood count and C-reactive protein and
HIV serology, is recommended.
Nobody questions vaccination for influenza and
pneumococcus pneumoniae, however, vaccinating for
hepatitis B virus (HBV) and hepatitis C virus (HCV) has
generated debate. In fact, no consensus regarding HCV
screening could be made by the experts. More recently, a
nationwide Spanish study of more than 2000 consecu-
tively recruited patients with IBD showed, in contrast to
previous reports, that the prevalence rates of HBV and
HCV infection were similar to those of the general
population [6]. This was confirmed in a French study
[7]. However, the frequency and severity of liver
dysfunction appear to be significantly higher in HBV-
infected patients than in HCV-infected patients. In the
study from the Spanish GETECCU (Grupo Español de
Enfermedades de Crohn y Colitis Ulcerosa), HBV
infection in patients with IBD resulted in liver dysfunc-
tion in more than one-third (36%) of patients,
including six cases of hepatic failure. Liver dysfunction
in HCV was less frequent (15.7%), and only one patient
developed hepatic failure [8]. The treatment with two or
more immunosuppressants was an independent pre-
dictor of HBV reactivation (odds ratio 8.75, 95% CI
1.16-65.66). Interestingly, the studies that have
reported on the degree of effective vaccination for
HBV show that only a minority of the patients with IBD
(range 12-48%) are effectively vaccinated. We recom-
mend that HBV and HCV serology be checked and
that patients negative for HBV receive vaccination. In
Figure 1. Serology and vaccination to be checked and performed before immunomodulators or biological therapy
The figure depicts the serology and vaccination to be performed in inflammatory bowel disease patients before immunomodulators or biological therapy (or
both) are started, as recommended by the consensus guidelines of the European Crohn’s and Colitis Organisation. anti-TNF, anti-tumor necrosis factor;
HBsAg+, positive for the surface antigen of HBV; HBV, hepatitis B virus; VZV, varicella zoster virus.
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immunomodulators or biologicals (or both), amino-
transferases and HCV viral load should be followed up.
In comparison with the more severe (opportunistic)
infections, benign infections such as the common cold,
bronchitis, warts, and herpes are found more frequently.
In a prospective cohort study with a follow-up of 207
patient-years, no difference in upper respiratory tract
infectionswasfoundbetweenazathioprine-takingpatients
and those not on purine analogues [9]. In contrast, the
rates of incidence of herpes flares and warts were
significantly increased in IBD patients receiving azathiopr-
ine. Where possible, stopping therapy may be recom-
mendedifflaresaretoofrequentorsevere.Iftherapyneeds
to be continued to maintain disease remission, daily oral
acyclovir (400 mg twice a day) is an option to prevent
frequent recurrences of herpes simplex disease.
Implications for clinical practice
IBD patients who need immunomodulators or biologi-
cal therapy should receive appropriate counseling
regarding the risk of infections and should receive a
number of vaccinations:
￿ First, all patients starting on an anti-TNF agent
should undergo tuberculin skin testing or an inter-
feron-gamma release assay as well as a chest X-ray to rule
out latent TB; if the assay is positive, anti-TB treatment
should be initiated at least 2 weeks prior to therapy.
￿ The ECCO consensus guidelines on opportunistic
infections furthermore recommend serology testing for
varicella zoster virus (VZV) and HBV and vaccination for
varicella (in case of negative serology for VZV and no
history of chickenpox), HBV, influenza (yearly), and
pneumococcal polysaccharide (every 3-5 years).
￿ Young females are advised to get human papilloma
virus vaccination.
￿ A baseline laboratory exam, including neutrophil,
eosinophil, and lymphocyte blood count, C-reactive
protein, and HIV serology, should be performed at the
time of diagnosis, and routine blood monitoring every
2-4 months should be continued while the patient is on
immunosuppressive agents.
￿ Mild viral infections like warts and herpes are more
frequent under immunomodulators or anti-TNF but, in
general, are no reason to stop therapy. If such an
infection is too invalidating for the patient, daily oral
acyclovir (400 mg twice a day) is an option in case of
herpes simplex disease.
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